Designing with novelty: why considering Structure-Activity Relationship alongside patent disclosures matters
Lead optimization is a decision-intensive phase of the drug discovery process, where medicinal chemists make targeted structural changes to improve potency, selectivity, or ADME properties, while managing timelines and scientific risk. At this stage, Structure–Activity Relationship (SAR) analysis is central to guiding compound optimization decisions. Alongside SAR, patent information provides important context by defining what chemistry has already been disclosed. In practice, however, SAR insights and patent data are often accessed through separate tools, which makes it harder to review activity trends alongside relevant prior art during compound design.
In this article, we outline the challenges of bringing SAR and patent context together during compound design, and describe how Discngine Ideation Analytics, with integrated patent search powered by Excelra’s GOSTAR™, enables this in a single workflow.
Complementary roles of SAR analysis and patent checking
SAR analysis guides compound design during lead optimization, driving series prioritization and decisions on what to synthesize next based on consistent activity and property trends. Patent checking adds a complementary perspective by addressing a different question: whether the same scaffold and substitution patterns have already been disclosed.
In practice, these perspectives can diverge. For example, SAR may show that para‑substitution on a given core consistently enhances potency. Viewed in isolation, this naturally points toward further exploration along that vector. However, patent disclosures may show that para‑substituted analogs of the same core are already widely described in prior art. Seeing both signals together early allows teams to pivot toward alternative design moves, such as shifting vectors, introducing heteroaryl replacements, or increasing sp³ character, that maintain the potency trajectory while improving differentiation.
The problem is that, in day-to-day workflows, SAR exploration and patent information are rarely considered side by side. SAR is reviewed continuously as new data emerges, whereas patent context is often consulted later or separately, once a direction has already gained momentum. This leads to rework and additional design iterations when overlap becomes apparent.
Why SAR and patent review remain separated
The main reason the separation between SAR and patent searching persists is that they are usually handled in different tools. Chemists usually summarize SAR in reports, then switch to a patent database to check what has been disclosed. The comparison is often manual, involving tasks such as copying identifiers, re-drawing structures, and then reconciling SAR conclusions with disclosed patent compounds across systems.
Beyond tooling, the data itself introduces additional friction. Patent data is organized very differently from internal SAR reports: it consists of large, heterogeneous datasets, with structures disclosed at varying levels of detail and activity data that is often sparse or inconsistent. Differences in naming conventions, salts, or stereochemistry can also make it harder to relate disclosed compounds directly to an internal series.
As a result, patent information tends to be harder to engage with during routine SAR review and is more likely to be scanned selectively rather than examined alongside internal analogs.
Integrating SAR and patent exploration
What is missing in many discovery programs is a single SAR‑native view that allows patent‑derived compounds to be examined alongside internal data and interpreted using the same SAR representations that guide compound design. This way, chemists can more easily recognize overlaps, see where SAR trends converge toward disclosed motifs, and weigh alternative design directions directly from the SAR view.
Discngine Ideation Analytics
This need to consider SAR and patent context together during compound design is addressed by Discngine Ideation Analytics, now enhanced with integrated patent search powered by Excelra’s GOSTAR™.
Ideation Analytics supports lead optimization by enabling medicinal chemists to generate clear, visually consistent SAR reports that organize internal bioactivity data into a format suitable for review, discussion, and decision‑making.
Ideation SAR Slides report preview: Collection of all datasets relevant compounds organized in highlighted, color-coded floating bubbles
Through the patent data integration, curated patent compounds and associated annotations can be brought directly into Ideation Analytics by simply entering a patent ID and retrieving the corresponding dataset from the patent database.
The “Import Patent Data” search function within Ideation Analytics
Established structuring approaches such as Matched Molecular Pairs (MMP) and R‑Group Decomposition (RGD) are applied consistently within Ideation Analytics to generate compound‑ or scaffold‑centric SAR reports, providing a structured view of substitutions and analog relationships for review and discussion.
When working with large or unfamiliar datasets, the SAR-structuring framework is complemented by Starting Point Suggestions, which help identify informative compounds or scaffolds from which to initiate SAR analysis. This allows teams to focus quickly on the most relevant chemistry without manually scanning the full dataset.
By keeping patent context visible, Ideation Analytics allows compound design to progress with a clearer view into disclosed chemical space. This supports innovation by helping teams focus their optimization efforts on differentiated regions of chemistry, rather than discovering overlaps only after the fact.
Conclusion
In lead optimization, compound design decisions are made through the interpretation of SAR reports used to discuss and justify the next steps. When patent-derived compounds can be examined within these SAR studies, prior art is no longer an external reference but part of the evidence used to evaluate and select design directions.
Discngine Ideation Analytics makes this side-by-side assessment possible thanks to integrated patent data, allowing chemists to reason about activity, structure, and disclosure constraints within a single, decision‑ready framework.
Wish to see Ideation Analytics in action? Reach out to our experts!